{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T11:10:46Z","timestamp":1697195446433},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00774-020-01170-6","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T13:18:45Z","timestamp":1605532725000},"page":"423-429","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw"],"prefix":"10.1007","volume":"39","author":[{"given":"Chihiro","family":"Kanno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuharu","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Kitabatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"1170_CR1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433\u2013443","journal-title":"Lancet"},{"key":"1170_CR2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HPCSG (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745\u2013755","journal-title":"N Engl J Med"},{"key":"1170_CR3","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","volume":"65","author":"RE Marx","year":"2007","unstructured":"Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397\u20132410","journal-title":"J Oral Maxillofac Surg"},{"key":"1170_CR4","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline. J Clin Oncol 37:2270\u20132290","journal-title":"J Clin Oncol"},{"key":"1170_CR5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"key":"1170_CR6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00774-019-01035-7","volume":"38","author":"S Hayashida","year":"2020","unstructured":"Hayashida S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H, Shibuya Y, Ueda N, Kirita T, Nakahara H, Shinohara M, Kondo E, Kurita H, Umeda M (2020) Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. J Bone Miner Metab 38:126\u2013134","journal-title":"J Bone Miner Metab"},{"key":"1170_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bone.2014.12.021","volume":"73","author":"T Ikeda","year":"2015","unstructured":"Ikeda T, Kuraguchi J, Kogashiwa Y, Yokoi H, Satomi T, Kohno N (2015) Successful treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) patients with sitafloxacin: new strategies for the treatment of BRONJ. Bone 73:217\u2013222","journal-title":"Bone"},{"key":"1170_CR8","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.joms.2019.03.040","volume":"77","author":"M El-Rabbany","year":"2019","unstructured":"El-Rabbany M, Lam DK, Shah PS, Azarpazhooh A (2019) Surgical management of medication-related osteonecrosis of the jaw is associated with improved disease resolution: a retrospective cohort study. J Oral Maxillofac Surg 77:1816\u20131822","journal-title":"J Oral Maxillofac Surg"},{"key":"1170_CR9","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1158\/0008-5472.CAN-11-3406","volume":"72","author":"B Sitohy","year":"2012","unstructured":"Sitohy B, Nagy JA, Dvorak HF (2012) Anti-VEGF\/VEGFR therapy for cancer: reassessing the target. Cancer Res 72:1909\u20131914","journal-title":"Cancer Res"},{"key":"1170_CR10","first-page":"15","volume":"20","author":"EE Vokes","year":"2006","unstructured":"Vokes EE, Chu E (2006) Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology 20:15\u201325","journal-title":"Oncology"},{"key":"1170_CR11","first-page":"170","volume":"1835","author":"HW Lee","year":"2013","unstructured":"Lee HW, Choi HJ, Ha SJ, Lee KT, Kwon YG (2013) Recruitment of monocytes\/macrophages in different tumor microenvironments. Biochim Biophys Acta 1835:170\u2013179","journal-title":"Biochim Biophys Acta"},{"key":"1170_CR12","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.4049\/jimmunol.173.4.2507","volume":"173","author":"ZF Yang","year":"2004","unstructured":"Yang ZF, Poon RT, Luo Y, Cheung CK, Ho DW, Lo CM, Fan ST (2004) Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J Immunol 173:2507\u20132515","journal-title":"J Immunol"},{"key":"1170_CR13","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/sj.jid.5701184","volume":"128","author":"S Pastore","year":"2008","unstructured":"Pastore S, Mascia F, Mariani V, Girolomoni G (2008) The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 128:1365\u20131374","journal-title":"J Invest Dermatol"},{"key":"1170_CR14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.0022-202X.2004.23478.x","volume":"123","author":"SK Repertinger","year":"2004","unstructured":"Repertinger SK, Campagnaro E, Fuhrman J, El-Abaseri T, Yuspa SH, Hansen LA (2004) EGFR enhances early healing after cutaneous incisional wounding. J Invest Dermatol 123:982\u2013989","journal-title":"J Invest Dermatol"},{"key":"1170_CR15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","volume":"26","author":"T van Cann","year":"2018","unstructured":"van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O et al (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26:869\u2013878","journal-title":"Support Care Cancer"},{"key":"1170_CR16","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","volume":"107","author":"B Beuselinck","year":"2012","unstructured":"Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schoffski P (2012) Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 107:1665\u20131671","journal-title":"Br J Cancer"},{"key":"1170_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5125\/jkaoms.2019.45.1.3","volume":"45","author":"AF Nifosi","year":"2019","unstructured":"Nifosi AF, Zuccarello M, Nifosi L, Hervas Saus V, Nifosi G (2019) Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology. J Korean Assoc Oral Maxillofac Surg 45:3\u20138","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"1170_CR18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1620\/tjem.247.75","volume":"247","author":"T Shibahara","year":"2019","unstructured":"Shibahara T (2019) Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 247:75\u201386","journal-title":"Tohoku J Exp Med"},{"key":"1170_CR19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S (2017) Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6\u201319","journal-title":"J Bone Miner Metab"},{"key":"1170_CR20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/0022034517732770","volume":"97","author":"A Soundia","year":"2018","unstructured":"Soundia A, Hadaya D, Esfandi N, Gkouveris I, Christensen R, Dry SM, Bezouglaia O, Pirih F, Nikitakis N, Aghaloo T, Tetradis S (2018) Zoledronate impairs socket healing after extraction of teeth with experimental periodontitis. J Dent Res 97:312\u2013320","journal-title":"J Dent Res"},{"key":"1170_CR21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","volume":"91","author":"FA Scappaticci","year":"2005","unstructured":"Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173\u2013180","journal-title":"J Surg Oncol"},{"key":"1170_CR22","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1200\/JCO.2009.21.9220","volume":"27","author":"CJ Allegra","year":"2009","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O\u2019Reilly S, Chu L, Azar CA, Wolmark N (2009) Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27:3385\u20133390","journal-title":"J Clin Oncol"},{"key":"1170_CR23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1245\/s10434-010-1366-8","volume":"18","author":"M Golshan","year":"2011","unstructured":"Golshan M, Garber JE, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P (2011) Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol 18:733\u2013737","journal-title":"Ann Surg Oncol"},{"key":"1170_CR24","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2008.21.3660","volume":"27","author":"E Jonasch","year":"2009","unstructured":"Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27:4076\u20134081","journal-title":"J Clin Oncol"},{"key":"1170_CR25","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3171\/2010.10.JNS101042","volume":"114","author":"AJ Clark","year":"2011","unstructured":"Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK (2011) Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 114:1609\u20131616","journal-title":"J Neurosurg"},{"key":"1170_CR26","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.3748\/wjg.v20.i20.6081","volume":"20","author":"L Fornaro","year":"2014","unstructured":"Fornaro L, Caparello C, Vivaldi C, Rotella V, Musettini G, Falcone A, Baldini E, Masi G (2014) Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review. World J Gastroenterol 20:6081\u20136091","journal-title":"World J Gastroenterol"},{"key":"1170_CR27","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/SAP.0b013e31824e5e57","volume":"71","author":"K Sharma","year":"2013","unstructured":"Sharma K, Marcus JR (2013) Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg 71:434\u2013440","journal-title":"Ann Plast Surg"},{"key":"1170_CR28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/iwj.13139","volume":"16","author":"JW Ahn","year":"2019","unstructured":"Ahn JW, Shalabi D, Correa-Selm LM, Dasgeb B, Nikbakht N, Cha J (2019) Impaired wound healing secondary to bevacizumab. Int Wound J 16:1009\u20131012","journal-title":"Int Wound J"},{"key":"1170_CR29","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJM199909023411006","volume":"341","author":"AJ Singer","year":"1999","unstructured":"Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341:738\u2013746","journal-title":"N Engl J Med"},{"key":"1170_CR30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1161\/01.CIR.92.1.11","volume":"92","author":"GT Stavri","year":"1995","unstructured":"Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD (1995) Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 92:11\u201314","journal-title":"Circulation"},{"key":"1170_CR31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4103\/2347-9264.165448","volume":"2","author":"TM Honnegowda","year":"2015","unstructured":"Honnegowda TM, Kumar P, Udupa EGP, Kumar S, Kumar U, Rao P (2015) Role of angiogenesis and angiogenic factors in acute and chronic wound healing. Plast Aesthet Res 2:243\u2013249","journal-title":"Plast Aesthet Res"},{"key":"1170_CR32","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.3390\/ijms16047159","volume":"16","author":"E Birkenhauer","year":"2015","unstructured":"Birkenhauer E, Neethirajan S (2015) A double-edged sword: the role of VEGF in wound repair and chemoattraction of opportunist pathogens. Int J Mol Sci 16:7159\u20137172","journal-title":"Int J Mol Sci"},{"key":"1170_CR33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00774-017-0872-1","volume":"36","author":"Y Akita","year":"2018","unstructured":"Akita Y, Kuroshima S, Nakajima K, Hayano H, Kanai R, Sasaki M, Sawase T (2018) Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic\/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice. J Bone Miner Metab 36:547\u2013559","journal-title":"J Bone Miner Metab"},{"key":"1170_CR34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijom.2019.07.016","volume":"49","author":"Z Guo","year":"2020","unstructured":"Guo Z, Cui W, Que L, Li C, Tang X, Liu J (2020) Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. Int J Oral Maxillofac Surg 49:298\u2013309","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1170_CR35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.matbio.2008.06.005","volume":"27","author":"Q Yang","year":"2008","unstructured":"Yang Q, McHugh KP, Patntirapong S, Gu X, Wunderlich L, Hauschka PV (2008) VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol 27:589\u2013599","journal-title":"Matrix Biol"},{"key":"1170_CR36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2005.07.145","volume":"335","author":"SE Aldridge","year":"2005","unstructured":"Aldridge SE, Lennard TW, Williams JR, Birch MA (2005) Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem Biophys Res Commun 335:793\u2013798","journal-title":"Biochem Biophys Res Commun"},{"key":"1170_CR37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/jcp.21511","volume":"217","author":"T Yi","year":"2008","unstructured":"Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, Woo KM, Ryoo HM, Kim GS, Baek JH (2008) Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. J Cell Physiol 217:409\u2013422","journal-title":"J Cell Physiol"},{"key":"1170_CR38","first-page":"317","volume":"44","author":"H Maeda","year":"1995","unstructured":"Maeda H, Ito N, Yokoyama M, Kamiya M, Kameyama Y (1995) Immunohistochemical study of EGFR expression in the excisional wound of hamster tongue. Jpn J Stomatol 44:317\u2013321","journal-title":"Jpn J Stomatol"},{"key":"1170_CR39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.oooo.2018.02.010","volume":"125","author":"T Higuchi","year":"2018","unstructured":"Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, Sasaki A (2018) Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 125:547\u2013551","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1170_CR40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10266-018-0362-5","volume":"106","author":"PJ Voss","year":"2018","unstructured":"Voss PJ, Steybe D, Poxleitner P, Schmelzeisen R, Munzenmayer C, Fuellgraf H, Stricker A, Semper-Hogg W (2018) Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. Odontology 106:469\u2013480","journal-title":"Odontology"},{"key":"1170_CR41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcms.2015.12.005","volume":"44","author":"AA Owosho","year":"2016","unstructured":"Owosho AA, Blanchard A, Levi L, Kadempour A, Rosenberg H, Yom SK, Farooki A, Fornier M, Huryn JM, Estilo CL (2016) Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: a series of thirteen patients. J Craniomaxillofac Surg 44:265\u2013270","journal-title":"J Craniomaxillofac Surg"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01170-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-020-01170-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01170-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T12:03:10Z","timestamp":1697112190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-020-01170-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01170-6","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the institutional review board of Fukushima Medical University Hospital (No. General 2020-010), and the study conformed to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}